Loading data for COYA — first visit, this takes a few seconds.

Coya Therapeutics, Inc. (COYA)

NasdaqCM: COYA · 实时价格 · USD

4.59

-0.27 (-5.56%)

收盘价： Aug 31, 2026, 7:01 PM

提醒

Alert

股价、关键数字和最新消息，都在这一页。

暂无数据

买价	3.48
市值	107M
营收（TTM）	8.02M
净利润（TTM）	-21.7M
	0.00
	-1.07
	n/a
	-2.43
市净率（TTM）	2.47
市销率（TTM）	13.34
财报日期	Nov 11, 2026

卖价	5.9
成交量	153,108
20日均量	194,287
开盘价	4.82
前收盘价	4.86
日内区间	4.55 - 4.82
52周区间	3.71 - 7.75
分析师	n/a
目标价	n/a
分红	n/a
除息日	n/a

关于 COYA

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function ...

[阅读更多]

行业 Biotechnology

板块 Healthcare

上市日期 Dec 29, 2022

员工人数 8

交易所 NasdaqCM

股票代码 COYA

官网 https://www.coyatherapeutics.com

公司完整简介

财务表现

2025年，Coya Therapeutics的营收为7.95M，较上一年的3.55M增长123.57%。净利润为-21.23M，增长42.64%。

财务报表

财报意外

Coya Therapeutics 已于 Aug 11, 2026 发布季度财报：

营收为 $251.15K 低于预期 $0, ， -2.61% 同比下滑.
每股收益为 -0.28 超出预期 0.08, ， 22.22% 同比增长.

下次财报发布时间

Coya Therapeutics, Inc. 的下次财报预计于 Nov 11, 2026, 开盘前。
分析师预计营收为 ... 升级

股价变动原因

新闻

2月前 · Zacks

Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?

Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.

3月前 · Pharmaceutical Technology

Coya Therapeutics secures FDA fast track status for COYA 302

COYA 302 is a proprietary biologic combination therapy that utilises a dual immunomodulatory approach.

3月前 · Exec Edge

Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs

By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said the recent outbreak of the hantavirus on a cruise ship highlights the need for broad-spectrum antiviral drugs such as NV-387. The hantavirus gets i...

3月前 · Exec Edge

NanoViricides to Participate at D. Boral Capital Global Conference in NYC

By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said it will participate at the D. Boral Capital Global Conference, to be held on May 7, 2026, at The Plaza Hotel in New York City. The company’s Presid...

3月前 · Exec Edge

NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA

By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said the FDA granted “Orphan Drug Designation” (ODD) to its clinical-stage, antiviral drug NV-387 for the treatment of measles, giving the company seven...

第 1 页，共 2 页

Coya Therapeutics, Inc. (COYA)